Literature DB >> 28842522

The Role of Hyperglycemia, Insulin Resistance, and Blood Pressure in Diabetes-Associated Differences in Cognitive Performance-The Maastricht Study.

Stefan L C Geijselaers1,2,3, Simone J S Sep1,2, Danny Claessens1, Miranda T Schram1,2, Martin P J van Boxtel4, Ronald M A Henry1,2, Frans R J Verhey4, Abraham A Kroon1,2, Pieter C Dagnelie2,5,6, Casper G Schalkwijk1,2, Carla J H van der Kallen1,2, Geert Jan Biessels3, Coen D A Stehouwer7,2.   

Abstract

OBJECTIVE: To study to what extent differences in cognitive performance between individuals with different glucose metabolism status are potentially attributable to hyperglycemia, insulin resistance, and blood pressure-related variables. RESEARCH DESIGN AND METHODS: We used cross-sectional data from 2,531 participants from the Maastricht Study (mean age ± SD, 60 ± 8 years; 52% men; n = 666 with type 2 diabetes), all of whom completed a neuropsychological test battery. Hyperglycemia was assessed by a composite index of fasting glucose, postload glucose, glycated hemoglobin (HbA1c), and tissue advanced glycation end products; insulin resistance by the HOMA of insulin resistance index; and blood pressure-related variables included 24-h ambulatory pressures, their weighted SDs, and the use of antihypertensive medication. Linear regression analyses were used to estimate mediating effects.
RESULTS: After adjustment for age, sex, and education, individuals with type 2 diabetes, compared with those with normal glucose metabolism, performed worse in all cognitive domains (mean differences in composite z scores for memory -0.087, processing speed -0.196, executive function and attention -0.182; P values <0.032), whereas individuals with prediabetes did not. Diabetes-associated differences in processing speed and executive function and attention were largely explained by hyperglycemia (mediating effect 79.6% [bootstrapped 95% CI 36.6; 123.4] and 50.3% [0.6; 101.2], respectively) and, for processing speed, to a lesser extent by blood pressure-related variables (17.7% [5.6; 30.1]), but not by insulin resistance. None of the factors explained the differences in memory function.
CONCLUSIONS: Our cross-sectional data suggest that early glycemic and blood pressure control, perhaps even in the prediabetic stage, may be promising therapeutic targets for the prevention of diabetes-associated decrements in cognitive performance.
© 2017 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28842522     DOI: 10.2337/dc17-0330

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  20 in total

1.  Dietary Polysaccharides in the Amelioration of Gut Microbiome Dysbiosis and Metabolic Diseases.

Authors:  Shokouh Ahmadi; Rabina Mainali; Ravinder Nagpal; Mahmoud Sheikh-Zeinoddin; Sabihe Soleimanian-Zad; Shaohua Wang; Gagan Deep; Santosh Kumar Mishra; Hariom Yadav
Journal:  Obes Control Ther       Date:  2017-12-18

Review 2.  The prebiotic potential of brewers' spent grain on livestock's health: a review.

Authors:  Emanuel Joel Lao; Noel Dimoso; Jofrey Raymond; Ernest Rashid Mbega
Journal:  Trop Anim Health Prod       Date:  2020-01-03       Impact factor: 1.559

Review 3.  Diabetes and Alzheimer's Disease: A Link not as Simple as it Seems.

Authors:  Isabel H Salas; Bart De Strooper
Journal:  Neurochem Res       Date:  2018-12-06       Impact factor: 3.996

4.  Role of delay discounting in predicting change in HBA1c for individuals with prediabetes.

Authors:  Leonard H Epstein; Rocco A Paluch; Jeff S Stein; Alexandra M Mellis; Teresa Quattrin; Lucy D Mastrandrea; Kyle A Bree; Mark H Greenawald; Warren K Bickel
Journal:  J Behav Med       Date:  2019-03-22

Review 5.  Executive Function and Diabetes: A Clinical Neuropsychology Perspective.

Authors:  Qian Zhao; Yonggang Zhang; Xiaoyang Liao; Weiwen Wang
Journal:  Front Psychol       Date:  2020-08-20

6.  Association between obesity and neurocognitive function in survivors of childhood acute lymphoblastic leukemia treated only with chemotherapy.

Authors:  Mayuko Iijima; Wei Liu; John C Panetta; Melissa M Hudson; Ching-Hon Pui; Deo Kumar Srivastava; Kevin R Krull; Hiroto Inaba
Journal:  Cancer       Date:  2021-04-29       Impact factor: 6.921

7.  The factors contributing to cognitive dysfunction in type 2 diabetic patients.

Authors:  San-Shan Xia; Wen-Lin Xia; Jiao-Jiao Huang; Hua-Jie Zou; Jing Tao; Yan Yang
Journal:  Ann Transl Med       Date:  2020-02

8.  Association of Cerebral Ischemia With Corneal Nerve Loss and Brain Atrophy in MCI and Dementia.

Authors:  Georgios Ponirakis; Ahmed Elsotouhy; Hanadi Al Hamad; Surjith Vattoth; Ioannis N Petropoulos; Adnan Khan; Hoda Gad; Fatima Al-Khayat; Mani Chandran; Marwan Ramadan; Marwa Elorrabi; Masharig Gadelseed; Rhia Tosino; Priya V Gawhale; Maryam Alobaidi; Shafi Khan; Pravija Manikoth; Yasmin H M Abdelrahim; Noushad Thodi; Hamad Almuhannadi; Salma Al-Mohannadi; Fatema AlMarri; Murtaza Qazi; Ahmed Own; Ziyad R Mahfoud; Ashfaq Shuaib; Rayaz A Malik
Journal:  Front Neurosci       Date:  2021-06-21       Impact factor: 4.677

9.  Cognitive function in early and later life is associated with blood glucose in older individuals: analysis of the Lothian Birth Cohort of 1936.

Authors:  Drew M Altschul; John M Starr; Ian J Deary
Journal:  Diabetologia       Date:  2018-06-02       Impact factor: 10.122

10.  Diabetes-related cognitive dysfunction: Hyperglycemia in the early stage might be a key?

Authors:  Hiroyuki Umegaki
Journal:  J Diabetes Investig       Date:  2018-03-08       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.